Biodesix and Inivata have announced a partnership to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for clinical applications in lung cancer.

Under the terms of the agreement, Inivata and Biodesix will conduct studies in non-small cell lung cancer (NSCLC) using Inivata’s NGS technology platform. Biodesix and Inivata will jointly fund studies to establish clinical utility for an NGS-based test and will initiate an observational study later this year.

Biodesix CEO David Brunel said, “Along with VeriStrat®, a serum protein test that is already commercially available to help physicians guide treatment decisions for patients with advanced NSCLC, the blood-based NGS tests we’re developing with Inivata will further drive towards precision medicine by guiding diagnosis, prognosis and monitoring for patients with NSCLC.”

Read the full story at